Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

Abstract A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8–30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53–222), with 5-year OS rate of 77% (95% CI: 61.0–87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.

[1]  H. Nahi,et al.  Characteristics and outcomes of patients with multiple myeloma aged 21–40 years versus 41–60 years: a multi‐institutional case‐control study , 2016, British journal of haematology.

[2]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[3]  K. McGlynn,et al.  Racial disparities in incidence and outcome in multiple myeloma: a population-based study. , 2010, Blood.

[4]  B. Barlogie,et al.  Survival and years of life lost in different age cohorts of patients with multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Trudel,et al.  Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  B. Barlogie,et al.  Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. , 2009, Blood.

[7]  H. Kaufmann,et al.  Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System , 2007, European journal of haematology.

[8]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[9]  M. Höglund,et al.  Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation , 2002, European journal of haematology.

[10]  R. Kyle,et al.  Multiple myeloma in young patients: clinical presentation and treatment approach. , 1998, Leukemia & lymphoma.

[11]  C. Klersy,et al.  Multiple myeloma in younger patients: the role of age as prognostic factor , 1998, Annals of Hematology.

[12]  R. Kyle,et al.  Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. , 1996, Archives of internal medicine.

[13]  R. Kyle,et al.  Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 Years , 1996, British journal of haematology.

[14]  H. Lazarus,et al.  Multiple myeloma in young men clinical course and electron microscopic studies of bone marrow plasma cells , 1980, Cancer.

[15]  R. Alexanian,et al.  Multiple myeloma in young persons. , 1976, Annals of internal medicine.

[16]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.